Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Inmune Bio, Inc. Director's Dealing 2021

Jun 24, 2021

34518_dirs_2021-06-24_d153812c-a276-4d97-9800-bdaab4f080ee.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2021-06-22

Reporting Person: Baracchini Edgardo Jr (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-22 Option (right to buy) $17.49 A 19025 Acquired 2031-06-21 Common Stock (19025) Direct

Footnotes

F1: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date.